Latest News
& Press Releases

Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone. It’s the most IPOs since 2021, when the industry recorded 78 during the height of the COVID-19 pandemic.

Follow along as BioSpace tracks job cuts and restructuring initiatives.

Haisco Pharmaceutical Group has been on a deal hot streak this year, inking major deals with Eli Lilly, AbbVie and more. The new company will take on one of Haisco’s core immunology assets.

While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.

Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily outcompete Novo Nordisk “given the high margins of a small-molecule therapy,” Truist analyst Srikripa Devarakonda told BioSpace.

After barely growing in 2024, biopharma employment in Massachusetts dropped 3.1% last year. R&D jobs dipped even more, by 3.9%. Biomanufacturing, however, went up.

While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.

The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication. The new target action date for the therapy is November 22.

The FDA has placed a clinical hold on RGX-121 after small nodules or cystic masses were detected in the spines of five patients enrolled in REGENXBIO’s registrational trial. The biotech no longer plans to resubmit the candidate—which was rejected in February—in the near term.

Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.

Five peer-reviewed studies published in nine months independently confirm high accuracy, robust panel optimization, and commercial viability of BioMark’s blood-based assay.

Agreement targets commercialization through the physical retail network of Nahdi Medical Company, Saudi Arabia’s largest pharmacy chain. Highlights Five-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order. Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia’s largest pharmacy chain. TempraMed believes the private-label structure can improve in-store commitment, pharmacist engagement and consumer promotion as the product is expected to be positioned as part of Nahdi’s own retail offering. Commercial launch is subject to applicable Saudi regulatory clearance, after which 60% of the initial purchase price becomes payable by bank transfer, with the remaining balance secured through a Letter of Credit